Literature DB >> 12727834

The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.

Antonio Rosato1, Silvia Dalla Santa, Alessia Zoso, Sofia Giacomelli, Gabriella Milan, Beatrice Macino, Valeria Tosello, Paolo Dellabona, Pier-Luigi Lollini, Carla De Giovanni, Paola Zanovello.   

Abstract

The TS/A mouse mammary adenocarcinoma is a poorly immunogenic tumor widely used in preclinical models of cancer immunotherapy. CTLs have often been indicated as important in TS/A tumor destruction, but their generation in this model has been rarely studied, nor have their precise target(s) been identified. We hypothesized that the gp70 Env product of an endogenous murine leukemia virus could be a target antigen for TS/A-specific CTLs and investigated this possibility in four different TS/A cell lines engineered with the genes that encode IFN-alpha, IFN-gamma, interleukin-4, and B7.1, respectively. All tumor cell lines expressed gp70, albeit at different levels, as demonstrated by reverse transcription-PCR analysis. Transfected tumor cells exhibited a delayed growth in vivo, and partial tumor regression. Spleen cells from mice that displayed tumor regression had high percentages of CD8(+) T cells that were specifically stained with L(d) tetramers loaded with gp70(423-431), the antigenic epitope of gp70 protein. Mixed leukocyte-peptide and mixed leukocyte-tumor cultures, set up by stimulating splenocytes with the immunogenic peptide and with transfected TS/A tumor cells, respectively, resulted in similar large increases in tetramer-reactive CD8(+) T cells and showed high lytic activity specific for gp70(423-431). Finally, in a Cold Target Inhibition assay, lytic activity of a mixed leukocyte-tumor culture was inhibited in an overlapping fashion by both the TS/A line used for restimulation and 293L(d) cells loaded with gp70(423-431) peptide, but not by 293L(d) cells pulsed with an irrelevant H-2 L(d) epitope, thus demonstrating that all or most of the cytotoxic activity was directed exclusively against this antigenic epitope.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

2.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Authors:  Claire Vanpouille-Box; Julie M Diamond; Karsten A Pilones; Jiri Zavadil; James S Babb; Silvia C Formenti; Mary Helen Barcellos-Hoff; Sandra Demaria
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

3.  Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Authors:  Julie M Diamond; Claire Vanpouille-Box; Sheila Spada; Nils-Petter Rudqvist; Jessica R Chapman; Beatrix M Ueberheide; Karsten A Pilones; Yasmeen Sarfraz; Silvia C Formenti; Sandra Demaria
Journal:  Cancer Immunol Res       Date:  2018-06-15       Impact factor: 11.151

Review 4.  The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.

Authors:  Sandra Demaria; Karsten A Pilones; Claire Vanpouille-Box; Encouse B Golden; Silvia C Formenti
Journal:  Radiat Res       Date:  2014-06-17       Impact factor: 2.841

5.  Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.

Authors:  M Zahidunnabi Dewan; Claire Vanpouille-Box; Noriko Kawashima; Sara DiNapoli; James S Babb; Silvia C Formenti; Sylvia Adams; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-10-09       Impact factor: 12.531

6.  Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Authors:  M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

7.  Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses.

Authors:  Maud Charpentier; Elena Garcia-Martinez; Karsten A Pilones; Camille Daviaud; Jeffrey Kraynak; Joseph Aryankalayil; Silvia C Formenti; Sandra Demaria
Journal:  Cancer Immunol Res       Date:  2020-06-12       Impact factor: 11.151

8.  The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

Authors:  Tyler R McCaw; Mei Li; Dmytro Starenki; Sara J Cooper; Mingyong Liu; Selene Meza-Perez; Rebecca C Arend; Donald J Buchsbaum; Andres Forero; Troy D Randall
Journal:  Cancer Immunol Immunother       Date:  2018-10-17       Impact factor: 6.968

9.  Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications.

Authors:  S Coral; A Covre; H J M G Nicolay; G Parisi; A Rizzo; F Colizzi; S Dalla Santa; E Fonsatti; E Fratta; L Sigalotti; M Maio
Journal:  Br J Cancer       Date:  2012-08-21       Impact factor: 7.640

10.  Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer.

Authors:  Mara De Martino; Camille Daviaud; Julie M Diamond; Jeffrey Kraynak; Amandine Alard; Silvia C Formenti; Lance D Miller; Sandra Demaria; Claire Vanpouille-Box
Journal:  Cancer Immunol Res       Date:  2020-10-22       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.